186 related articles for article (PubMed ID: 12736246)
21. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
[TBL] [Abstract][Full Text] [Related]
22. Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Collen D; Lijnen HR; Vanderschueren S
Verh K Acad Geneeskd Belg; 1995; 57(3):183-96; discussion 196-8. PubMed ID: 7483814
[TBL] [Abstract][Full Text] [Related]
23. [Staphylokinase and its mutants: a new generation of thrombolytic agents].
Lebrazi J; Elalamy I; Helft G; Samama MM
J Mal Vasc; 1998 Apr; 23(2):92-8. PubMed ID: 9608920
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase.
Vanwetswinkel S; Plaisance S; Zhi-Yong Z; Vanlinthout I; Brepoels K; Lasters I; Collen D; Jespers L
Blood; 2000 Feb; 95(3):936-42. PubMed ID: 10648406
[TBL] [Abstract][Full Text] [Related]
25. Clot-Targeted Nanogels for Dual-Delivery of AntithrombinIII and Tissue Plasminogen Activator to Mitigate Disseminated Intravascular Coagulation Complications.
Sheridan A; Nellenbach K; Pandit S; Byrnes E; Hardy G; Lutz H; Moiseiwitsch N; Scull G; Mihalko E; Levy J; Brown AC
ACS Nano; 2024 Jun; 18(24):15517-15528. PubMed ID: 38836363
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
28. Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities.
Chen H; Mo W; Zhang Y; Su H; Ma J; Yao R; Zhang S; Ge J; Song H
Eur J Pharmacol; 2007 Jul; 566(1-3):137-44. PubMed ID: 17451675
[TBL] [Abstract][Full Text] [Related]
29. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
[TBL] [Abstract][Full Text] [Related]
30. Spirulan from blue-green algae inhibits fibrin and blood clots: its potent antithrombotic effects.
Choi JH; Kim S; Kim SJ
J Biochem Mol Toxicol; 2015 May; 29(5):240-8. PubMed ID: 25651404
[TBL] [Abstract][Full Text] [Related]
31. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Meddahi S; Samama MM
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.
Mirshahi M; Soria J; Soria C; Faivre R; Lu H; Courtney M; Roitsch C; Tripier D; Caen JP
Blood; 1989 Aug; 74(3):1025-30. PubMed ID: 2502207
[TBL] [Abstract][Full Text] [Related]
33. Antithrombin-independent effects of heparins on fibrin clot nanostructure.
Yeromonahos C; Marlu R; Polack B; Caton F
Arterioscler Thromb Vasc Biol; 2012 May; 32(5):1320-4. PubMed ID: 22362760
[TBL] [Abstract][Full Text] [Related]
34. Staphylokinase as a plasminogen activator component in recombinant fusion proteins.
Szarka SJ; Sihota EG; Habibi HR; Wong S
Appl Environ Microbiol; 1999 Feb; 65(2):506-13. PubMed ID: 9925575
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
Hauptmann J; Glusa E
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide.
Römisch J; Stöhr HA; Stauss H; Koschinsky R; Stüber W; Pâques EP
Thromb Haemost; 1994 Mar; 71(3):320-4. PubMed ID: 8029796
[TBL] [Abstract][Full Text] [Related]
37. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots.
Prager NA; Abendschein DR; McKenzie CR; Eisenberg PR
Circulation; 1995 Aug; 92(4):962-7. PubMed ID: 7641380
[TBL] [Abstract][Full Text] [Related]
38. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
39. Construction and characterization of a novel staphylokinase variant with thrombin-inhibitory activity.
Wang M; Wang Y; Wang J; Zou M; Liu S; Xu T; Cai X; Wu C; Wang J; Xu D
Biotechnol Lett; 2009 Dec; 31(12):1923-7. PubMed ID: 19685208
[TBL] [Abstract][Full Text] [Related]
40. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
